Rising Clindamycin Resistance in Group A Streptococcus in an Irish Healthcare Institution

• DOI: 10.1099/acmi.0.000772.v3
• Publication Date: 2024-06-18T10:25:07Z
• Authors: Susan Lapthorne; Robert McWade; Nuala Scanlon; Saoirse Ní Bhaoill; Aoife Page; Clare O'Donnell; Gabriela Dornikova; Margaret Hannan; Breda Lynch; Maureen Lynch; Deirdre Brady
• Keywords: Institution

Group A streptococcus (GAS) can cause serious invasive disease in humans with a high mortality rate. An increase GAS infections was reported Ireland 2022, and this has been sustained 2023 is paralleled by similar trends Europe. Rising antimicrobial resistance global problem presents significant challenges to clinicians treating infection. There clindamycin isolates 2022. We examined susceptibility patterns of our institution Although all included study were susceptible penicillin, we noted rate 28% isolates. also tetracycline erythromycin resistance, 43% 30%, respectively. Our results could have implications for empiric prescribing guidelines skin soft tissue infections, which often include as it inhibits the production many virulence factors associated GAS. In addition, macrolides are first line recommended antibiotic patients anaphylaxis penicillin. This emphasises importance continuous surveillance testing non-invasive order monitor increasing resistance.